Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • American Society of Nephrology (ASN) - Kidney Week 2025

American Society of Nephrology (ASN) - Kidney Week 2025

November 5 - 9, 2025

  1. All
  2. aHUS
  3. CSA-AKI
  4. HSCT-TMA
  5. HypoPT
  6. IgAN
  7. LN
  8. Other

HTML

Baseline characteristics and treatment patterns in chinese patients with atypical hemolytic uremic syndrome: preliminary results from a prospective, observational study

PDF

Real-world effectiveness of ravulizumab among patients with atypical hemolytic uremic syndrome (aHUS) in underrepresented minority subgroups: a physician panel-based chart review study

PDF

Ravulizumab in atypical hemolytic uremic syndrome: time-to-treatment analysis from a phase 3 trial

PDF

Long-term clinical impact of cardiac surgery-associated AKI in patients with stage 3 or 4 CKD: LOTUS study

PDF

Ravulizumab treatment in pediatric patients with HSCT-TMA is associated with lower rates of hypertension, proteinuria reduction, and high survival

PDF

Eneboparatide Induces normalization of urinary calcium in hypoparathyroidism through prolonged PTH1R activation

HTML

Blood pressure control in patients with IgA nephropathy on ravulizumab: prespecified analysis of the phase 2 SANCTUARY trial

PDF

Change in soluble biomarker levels in patients with IgAN: analysis of the phase 2 trial of ravulizumab (SANCTUARY)

HTML

Soluble Biomarkers in IgAN: Analysis of Baseline Data from the Phase 2 Trial of Ravulizumab (SANCTUARY)

PDF

Efficacy and safety of ALXN2050 in IgAN: results of a randomized, double-blind, placebo-controlled phase 2 trial

PDF

Efficacy of ravulizumab on proteinuria response by baseline proteinuria or eGFR: post hoc analysis of the SANCTUARY trial

PDF

Evaluation of hematuria in patients treated with ravulizumab in the phase 2 SANCTUARY trial

PDF

Prespecified analysis of expanded safety outcomes of ravulizumab in IgAN from the SANCTUARY trial

PDF

Proteomic profiling of 24-hour urine in the phase 2 IgAN SANCTUARY trial

PDF

Efficacy and safety of ALXN2050 (vemircopan) in lupus nephritis: results of a phase 2 trial

PDF

Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis

HTML

Baseline characteristics and treatment patterns in chinese patients with atypical hemolytic uremic syndrome: preliminary results from a prospective, observational study

PDF

Ravulizumab in atypical hemolytic uremic syndrome: time-to-treatment analysis from a phase 3 trial

PDF

Real-world effectiveness of ravulizumab among patients with atypical hemolytic uremic syndrome (aHUS) in underrepresented minority subgroups: a physician panel-based chart review study

PDF

Long-term clinical impact of cardiac surgery-associated AKI in patients with stage 3 or 4 CKD: LOTUS study

PDF

Ravulizumab treatment in pediatric patients with HSCT-TMA is associated with lower rates of hypertension, proteinuria reduction, and high survival

PDF

Eneboparatide Induces normalization of urinary calcium in hypoparathyroidism through prolonged PTH1R activation

HTML

Blood pressure control in patients with IgA nephropathy on ravulizumab: prespecified analysis of the phase 2 SANCTUARY trial

PDF

Change in soluble biomarker levels in patients with IgAN: analysis of the phase 2 trial of ravulizumab (SANCTUARY)

HTML

Soluble Biomarkers in IgAN: Analysis of Baseline Data from the Phase 2 Trial of Ravulizumab (SANCTUARY)

PDF

Efficacy and safety of ALXN2050 in IgAN: results of a randomized, double-blind, placebo-controlled phase 2 trial

PDF

Efficacy of ravulizumab on proteinuria response by baseline proteinuria or eGFR: post hoc analysis of the SANCTUARY trial

PDF

Evaluation of hematuria in patients treated with ravulizumab in the phase 2 SANCTUARY trial

PDF

Prespecified analysis of expanded safety outcomes of ravulizumab in IgAN from the SANCTUARY trial

PDF

Proteomic profiling of 24-hour urine in the phase 2 IgAN SANCTUARY trial

PDF

Efficacy and safety of ALXN2050 (vemircopan) in lupus nephritis: results of a phase 2 trial

PDF

Pregnancy outcomes following ravulizumab exposure: a pharmacovigilance analysis

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States